

This is not an ADB material. The views expressed in this document are the views of the author/s and/or their organizations and do not necessarily reflect the views or policies of the Asian Development Bank, or its Board of Governors, or the governments they represent. ADB does not guarantee the accuracy and/or completeness of the material's contents, and accepts no responsibility for any direct or indirect consequence of their use or reliance, whether wholly or partially. Please feel free to contact the authors directly should you have queries.

EXPERIENCE SHARING


Tackling the Burden of Non-Communicable Diseases: BPJS Kesehatan's Policy and Program Responses

Mahlil Ruby

Director of Planning and Development

SECURE WEBINAR 21

Jakarta, May 15th, 2025





Curriculum Vitae

Mahlil Ruby, MD., MPH., DrPH
Director of Planning and Development
Social Security Administrative Body for Health

Place and Date of Birth: Bireun, September 17

P: +62 811 182025

E: mahlil.ruby@bpjs-kesehatan.go.id

Education Experience:

- University of Syiah Kuala Banda Aceh, General Practitioner, Bachelor Degree (1992)
- University of Indonesia, Department of Health Administration and Policy, Master Degree (2000)
- University of Indonesia, Public Health (Public Health Policy, Health Economics & Insurance), Doctorate Degree (2007)


Work Experience:

- Head of Public Health Center in Aceh Province (more than 10 years)
- Health Expert for Commission IX of National Parliament (2009)
- Health Advisor for Public Services I RTI (2009-2013)
- National Advisor for Social Health Insurance GIZ Social Protection Program (SPP)
- National Social Health Insurance (JKN) Specialist DAI USAID Jalin (2018 2020)
- Director of Planning and Development of BPJS Kesehatan (2021 present)
- Lecturer and Examiner of Doctoral Program, Faculty of Public Health, University of Indonesia






1A. BPJS KESEHATAN BUSINESS MODEL IN JKN PROGRAM




Single Scheme, 98,9% Coverage (279 M), Deficit (-) → Surplus (+), Down payment, increased tariff & satisfaction, OOP 49.7% → 25%



1C. NATIONAL HEALTH ACCOUNT (INDONESIA)

(in Trilion rupiah)





1D. HEALTH CARE SERVICE UTILIZATION

HEALTH CARE EXPENDITURE

2024

IDR 175.07 trillion (USD 10.26 billion)

2023

IDR 158.85 trillion (USD 9.31 billion)

2014

IDR 42.65 trillion (USD 2.50 billion)

Total health care expenditure in 11 years of JKN implementation

IDR 1,087.4 Trillion (USD 63.77 billion)

Health care service utilization

2024


1.9 million visits/day

700.42 million visits/year

2014

252 thousand visits/day

92.3 million visits/year




- √ Catastrophic expenditure took part about 24-31% of the total health care expenditure
- √ The total of catastrophic expenditure from 2014 to 2024 is no less than IDR 235 trillion (USD 13.78 billion)
- √ Catastrophic expenditure due to heart diseases is the largest proportion







1E. CHRONIC DISEASE PATIENT (JKN PARTICIPANTS)

Trend Total Chronic Disease Patient per Diagnosis 2002-2024 (in mio)





Trends in Health Care expenditure VS Chronic Disease Expenditure in Referral Care Facilities




- ✓ Chronic Disease Patient (JKN Participants) who receive services from JKN continue to increase every year.
- ✓ The highest average annual increase are Hypertension (average 0.9 million), Diabetes (average 0.6 million) and Heart Disease (average 0.4 million)
- ✓ If this condition is not managed optimally, it can lead to financial instability. In long term, it will have an impact on the deficit.





1F. CHRONIC DISEASE CASES (JKN PARTICIPANTS) AND RISK FACTORS

Total of Chronic Disease Cases per Province in 2024 (Per mil)



In terms of rate (permil of JKN participants) the highest are in the Province of DIY (70 permil), DKI Jakarta and Bali (58 permil)

Chronic Disease Risk Factors:


- 1. Lack of physical activity (33,5% population ≥10 years old)
- 2. Unhealthy Diet (95,5% vegetables/fruits consumption <5 portion/day)
- 3. Smoking (28,8% population ≥10 years old)
- 4. Excessive alcohol consumption (~3,0% (estimation))
- 5. Overweight (21,8% population ≥18 years old (BMI ≥25)
- 6. Age (~26,3% population)
- 7. Sex (50,3% Female, 49,7% Male)
- 8. Genetic (10-30% depend on kind of disease)

Source : Riskesdas 2018, BPS 2020, WHO 2018.





1G. CHRONIC DISEASE PYRAMID (2024)







2A. WHY CONTROLLING DM AND HT IS IMPORTANT

Hypertension and diabetes mellitus are mother of diseases.

Being a silent killer: often asymptomatic until severe complications arise.



Type of Complication	Increased Risk (compared to non-diabetics)	Prevalence in Diabetes Patients	Main Reference Sources
Heart Disease	2-4 times higher	±30%	Johns Hopkins
			Heart Foundation Australia
Hypertension	Very high (>2x)	±66%	Medical News Today
			Johns Hopkins
Stroke	2-5 times higher	±11.2%	BMJ Open
			BMC Public Health

Diabetes like **"gateways"** or contributes to other serious health problems.



More than **49,3 trillion rupiahs** were spent in 2024 to treat DM, HT, stroke, kidney failure, and heart disease.

HYPERTENSION AND DIABETES PREVENTION PROGRAM



Hypertension and diabetes must be controlled



Hypertension and diabetes mellitus reduces productivity and quality of life.







2B. DIABETES MELLITUS AND HYPERTENSION COVERAGE IN THE JKN PROGRAM

Presidential Decree Number 59 year 2024 on National Health Insurance











HEALTH PROMOTION

Education and monitoring for members who have not shown risks, at risk, or have been diagnosed



Includes treatmend for pre-diabetic and prehypertension patients

HEALTH SCREENING

Early detection for DM and Hypertension



- DM screening by blood glucose examination
- Hypertension screening by blood pressure examination
- Stroke and heart disease screening by blood pressure examination

CHRONIC DISEASE TREATMENT

DM and HT medication every month



Both in primary care and hospital care

REFER BACK PROGRAM (PRB)

Members with controlled condition for DM and HT in hospital care may proceed the medication in primary care



Prescription is made by doctors and the medicine is provided by the PRB Pharmaceutical center (Apotek PRB)

DISEASE MANAGEMENT PROGRAM (PROLANIS)

PROLANIS aims to stabilize DM and Hypertension members' clinical condition.




Blood glucose examination, HbA1C, cholesterol examination, physical activity, and personal health promotion is included in PROLANIS benefit





2C.PROMOTIVE PREVENTIVE SERVICES IN JKN SCHEME



Health Consultation

- Supporting Examination
- Medicine Services

SICK

- Education and Exercise
- Health Status Monitoring

Drug services for 9 diseases:

- 1. Diabetes Mellitus
- 2. Hypertension
- 3. Heart

Referred Back

- 4. Asthma
- 5. Chronic Obstructive **Pulmonary Disease**
- 6. Epilepsy
- 7. SLE
- 8. Schizophrenia
- 9. Strokre

Health History Screening

43,9 mio (target 33 mio)

Health History Screening

2,5 mio WA Blast

Risk Participant will receive

Specific Health Screening



DM Screening

IVA Screening

1,6_{mio} Hypertension Screening

179 thousand

Papsmear Screening PARTICIPANT HEALTH STATUS CONTROLLED

In the JKN program there are 14 screening programs, including screening for diabetes mellitus, hypertension, stroke, and ischemic heart diseases.

Media

BEHAVIOR

3. Exercise

2D. CHRONIC DISEASE MANAGEMENT PROGRAM (PROLANIS)

Tertiary Prevention



BPJS Kesehatan

What is PROLANIS?

A health service system with an integrated proactive approach, involving Participants, Health Facilities and Health BPJS in the framework of health care for participants with chronic diseases, especially Type 2 DM and Hypertension to achieve optimal quality of life with effective and efficient health care costs.

Goal: Encouraging participant independence, increasing participant health status, increasing participant satisfaction, and controlling health service costs in the long term.

PROLANIS EVALUATION Per Dec 2024



622.291 Members of Prolanis DM



1.001.124 members of Prolanis Hypertension



PROLANIS activity

Health

Done through direct consultation / teleconsultation

Consultation • Performed as needed at any time.



Medicine Service

- Given every month to Prolanis participants
- For Prolanis-PRB participants: mechanism for administering PRB drugs.
- For pure Prolanis participants: Mechanism of capitation drug administration



Lab Tests

- Fasting blood sugar test: 1x/month
- HbA1C: 1x/6 months
- Blood chemistry tests (Total cholesterol, HDL, LDL, Triglycerides, Creatinine, Urea, Microalbuminuria): 1x/6 months



Education and physical activities

- Conducted every month
- Can be carried out ofline or virtually via Zoom, Whatsapp Video, Ms. Teams, etc

CHALLENGES:

- Not all DM and HT patients are registered by their primary care providers as a Prolanis member.
- The insufficiency of drugs and medical devices.
- Awareness from Prolanis members of their own health status







2E. REFERRAL BACK PROGRAM (PRB)



Referral Back Program (PRB)

refers to the transfer of responsibilities for healthcare services from specialist or subspecialist doctors at referral care facilities to primary care facilities for chronic patients in stable condition, through referral letter.





Challenges in implementing Referral Back Program (PRB):

- ✓ Availability of medications at Referral Back Program pharmacies, including compliance with E-Monev and E-Purchasing accounts.
- ✓ Education and monitoring of treatment for participants by Primary Health Care Facilities
- ✓ Collaboration and synergy between Primary Health Care Facilities and Referral Care Facilities in managing Referral Back Program participants.




2F. PROLANIS INDICATOR IN THE PAY FOR PERFORMANCE (KBK) SCHEME

Hypertension and diabetes mellitus should have been prevented by the primary care providers.

As a response to the data of Diabetes and Hypertension cases, BPJS Kesehatan enacted a pay for performance (KBK) scheme.

- Primary care providers are assessed every month before the due for capitation payment.
- Capitation payment will be adjusted ranging from 15% of total capitation received by the primary care providers.
- One of the indicator is related to PROLANIS disease management program.



2G. DIGITAL INNOVATION IN TACKLING NCD



1st Model, Telehealth : 23 Primary Health Care Facilities

2nd Model, Telemedicine: 124 Primary Health Care Facilities

3rd Model, Teleconsultation:
5 Primary Health Care

Facilities

Telemedicine provides 3
models for health consultations
with GP and Specialist through
JKN Mobile



7.517 PCPs

2.016 ref. care facilities

I-Care JKN makes it easy for doctors to find out the patient's health service history from other health facilities.



BUGAR helps participants to provide the information about blood pressure, glucose levels, and mineral levels for real time health monitoring.





3.054
Referral care

Biometric validation for participant's eligibility through Finger Print at hospitals in order to obtained health care services



2.191

Referral care facilities

Electronic SEP by digital claim

(no paper print) and signature by the participant. Validation via FP & QR Code



HEALTH HISTORY SCREENING

in the form of filling out a selfassessment by the Participant and/or FKTP doctor once a year, to determine the participant's potential risk of disease.





KEY TAKEAWAYS





Strengthening the **Role of Primary Care**

Reinforce the role of Primary Health Care Facilities as gatekeepers

Enhance the use of primary teleconsultation as the first patient contact.



Improving PROLANIS & Referral Back Program

Improve healthcare worker competencies

Ensure infrastructure, medicine availability, and supporting facilities (including digital innovation)

Consider performancebased capitation incentives



Engagement

Increase participant awareness and compliance with Referral Back Program-Prolanis disease management targets.

Enhance participant's health literacy

Utilize digital health tools to facilitate active participation



Cross Sector Collaboration

Harmonize policies between multisectors

Integrate health programs with local government initiatives

Leverage digital platforms for multi-stakeholder coordination





TERIMAKASIH

www.bpjs-kesehatan.go.id

- bpjskesehatan_ri
- ø bpjskesehatan_ri
- BPJS Kesehatan
- BPJS Kesehatan
- BPJSKesehatanRI









